Five-year outcomes from randomized, phase III trials: Nivolumab vs. Docetaxel in previously treated non–small-cell lung cancer

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer – Journal of Clinical Oncology

Commentary on Twitter

At 5 years of follow up in CheckMate 017 and 057 trials, nivolumab continues to demonstrate a survival benefit vs docetaxel in patients with previously-treated advanced NSCLC https://t.co/oswZhdAPTW #JCO #lcsm #immunoonc pic.twitter.com/4FZJlfig99

— ASCO Publications (@ASCO_pubs) February 9, 2021